Kedrion
Kedrion SpA is an Italian multinational biopharmaceutical enterprise specializing in the collection, fractionation, and manufacturing of plasma-derived medicinal products, prominently featuring human albumin, immunoglobulins, and coagulation factors utilized in the treatment of rare and serious immunological, neurological, and hematological diseases. The company operates specialized blood plasma collection centers and advanced fractionation manufacturing facilities, supplying essential biological therapies to hospitals and healthcare systems in over 100 countries. Its core business operations encompass plasma collection logistics, biopharmaceutical protein fractionation, clinical medicine manufacturing, and global wholesale distribution. Revenue is derived directly from the global wholesale sale of plasma-derived therapeutics to medical distributors and healthcare providers. Kedrion holds an established global market position in plasma-derived medicine manufacturing. The company is headquartered in Castelvecchio Pascoli, Italy, operating as a specialized biopharmaceutical enterprise.
6 of the funds FundTelligence covers report a position in Kedrion.
- Legal name
- Kedrion SpA
- Sector
- Health Care
- Country
- Italy
- Funds holding it
- 6
Funds holding Kedrion
- Schroder ISF EURO High Yield — Schroders · 1.1 % (full portfolio disclosed, June 2026)
- Allianz Global High Yield — Allianz Global Investors · 0.89 % (largest positions only, September 2026)
- Templeton Global High Yield — Franklin Templeton · 0.49 % (full portfolio disclosed, September 2026)
- Schroder ISF Global High Yield — Schroders · 0.41 % (full portfolio disclosed, June 2026)
- Alfred Berg Global High Yield — Alfred Berg · 0.4 % (full portfolio disclosed, June 2026)
- Schroder ISF Sustainable Global Multi Credit — Schroders · 0.18 % (full portfolio disclosed, December 2025)